Investors bought shares of Allergan PLC (NYSE:AGN) on weakness during trading hours on Tuesday. $148.64 million flowed into the stock on the tick-up and $126.10 million flowed out of the stock on the tick-down, for a money net flow of $22.54 million into the stock. Of all stocks tracked, Allergan PLC had the 13th highest net in-flow for the day. Allergan PLC traded down ($1.79) for the day and closed at $242.64

A number of analysts recently weighed in on AGN shares. Leerink Swann reaffirmed a “buy” rating and issued a $340.00 price objective on shares of Allergan PLC in a research note on Tuesday, April 5th. Cowen and Company reissued a “buy” rating on shares of Allergan PLC in a research report on Tuesday, April 5th. Nomura Holdings Inc. reissued a “buy” rating and set a $330.00 price target (down from $350.00) on shares of Allergan PLC in a research report on Tuesday, April 5th. Canaccord Genuity reissued a “buy” rating and set a $320.00 price target (down from $340.00) on shares of Allergan PLC in a research report on Thursday, March 31st. Finally, Deutsche Bank AG decreased their price target on shares of Allergan PLC from $339.00 to $282.00 and set a “buy” rating for the company in a research report on Wednesday, April 6th. Six research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $306.06.

The company has a 50 day moving average of $238.47 and a 200-day moving average of $256.18. The company has a market cap of $95.98 billion and a price-to-earnings ratio of 21.71.

Allergan PLC (NYSE:AGN) last announced its quarterly earnings data on Tuesday, May 10th. The company reported $3.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.01. The company earned $3.80 billion during the quarter, compared to analysts’ expectations of $3.97 billion. The company’s revenue was up 48.1% on a year-over-year basis. Equities research analysts forecast that Allergan PLC will post $14.20 earnings per share for the current year.

In related news, CFO Maria Teresa Hilado acquired 661 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The stock was acquired at an average price of $241.57 per share, for a total transaction of $159,677.77. Following the purchase, the chief financial officer now owns 11,957 shares of the company’s stock, valued at approximately $2,888,452.49. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nesli Basgoz sold 459 shares of Allergan PLC stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total value of $103,320.90. Following the completion of the transaction, the director now owns 5,242 shares of the company’s stock, valued at approximately $1,179,974.20. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. Eaton Vance Management boosted its position in shares of Allergan PLC by 276.7% in the fourth quarter. Eaton Vance Management now owns 793,555 shares of the company’s stock valued at $247,986,000 after buying an additional 582,890 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Allergan PLC by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 23,246,431 shares of the company’s stock valued at $7,264,510,000 after buying an additional 576,325 shares during the last quarter. State of Tennessee Treasury Department boosted its position in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock valued at $145,669,000 after buying an additional 268,357 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of Allergan PLC during the fourth quarter valued at about $48,916,000. Finally, State of Wisconsin Investment Board boosted its position in shares of Allergan PLC by 44.6% in the fourth quarter. State of Wisconsin Investment Board now owns 496,155 shares of the company’s stock valued at $155,048,000 after buying an additional 153,010 shares during the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.